PACB

2.34

20.62% 0.40

Dopo l'orario di chiusura: 2.35 0.01 +0.43%

Pacific Biosciences Of California Inc (PACB)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché PACB Giù? Forum Previsione

Precedente Chiudi:

$1.94

Aprire:

$2.065

Volume 24 ore:

22.62M

Relative Volume:

2.92

Capitalizzazione di mercato:

$702.87M

Reddito:

$188.87M

Utile/perdita netta:

$-400.38M

Rapporto P/E:

-1.56

EPS:

-1.5

Flusso di cassa netto:

$-260.90M

1 W Prestazione:

+15.84%

1M Prestazione:

+82.81%

6M Prestazione:

+110.81%

1 anno Prestazione:

+7.83%

Intervallo 1D:

$2.05

$2.37

Intervallo di 1 settimana:

$1.91

$2.37

Portata 52W:

$0.8511

$2.72

Pacific Biosciences Of California Inc Stock (PACB) Company Profile

Nome

Pacific Biosciences Of California Inc

Settore

Healthcare (1135)

Industria

Medical Devices (144)

Telefono

650-521-8000

Indirizzo

1305 O'BRIEN DRIVE, MENLO PARK, CA

Dipendente

575

Cinguettio

@pacbio

Prossima data di guadagno

2024-11-07

Ultimi documenti SEC

PACB's Discussions on Twitter

Confronta PACB con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
PACB Pacific Biosciences Of California Inc	2.34	582.72M	188.87M	-400.38M	-260.90M	-1.50
ABT Abbott Laboratories	123.62	216.79B	43.84B	13.90B	6.92B	7.9725
BSX Boston Scientific Corp	100.72	149.02B	19.35B	2.78B	3.49B	1.8696
SYK Stryker Corp	356.24	141.06B	24.38B	2.94B	4.02B	7.6145
MDT Medtronic Plc	90.70	116.68B	34.20B	4.69B	5.30B	3.6218
EW Edwards Lifesciences Corp	82.45	49.01B	5.88B	1.34B	577.90M	2.3455

Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-11-11	Downgrade	UBS	Buy → Neutral
2024-06-03	Ripresa	Jefferies	Buy
2024-04-22	Downgrade	JP Morgan	Overweight → Neutral
2024-04-18	Downgrade	Goldman	Buy → Neutral
2023-12-14	Iniziato	Guggenheim	Neutral
2023-12-14	Iniziato	Stephens	Overweight
2023-12-13	Iniziato	Wolfe Research	Peer Perform
2023-11-17	Aggiornamento	UBS	Neutral → Buy
2023-10-31	Aggiornamento	Cantor Fitzgerald	Neutral → Overweight
2023-09-28	Iniziato	Bernstein	Outperform
2023-07-05	Ripresa	JP Morgan	Overweight
2023-06-30	Iniziato	Goldman	Buy
2023-05-10	Iniziato	Barclays	Equal Weight
2023-03-31	Aggiornamento	TD Cowen	Market Perform → Outperform
2023-02-02	Iniziato	UBS	Neutral
2023-01-20	Downgrade	Cantor Fitzgerald	Overweight → Neutral
2023-01-05	Iniziato	Scotiabank	Sector Outperform
2022-01-21	Ripresa	Cantor Fitzgerald	Overweight
2022-01-06	Ripresa	Piper Sandler	Neutral
2021-10-15	Ripresa	Cowen	Market Perform
2021-09-27	Iniziato	Canaccord Genuity	Buy
2021-02-11	Aggiornamento	Piper Sandler	Neutral → Overweight
2020-11-03	Downgrade	Piper Sandler	Overweight → Neutral
2020-10-02	Aggiornamento	JP Morgan	Neutral → Overweight
2020-09-09	Iniziato	Morgan Stanley	Equal-Weight
2020-06-02	Ripresa	Cantor Fitzgerald	Overweight
2020-03-09	Ripresa	Cantor Fitzgerald	Overweight
2019-10-15	Aggiornamento	Piper Jaffray	Neutral → Overweight
2019-04-02	Downgrade	Stephens	Overweight → Equal-Weight
2018-10-19	Iniziato	Cowen	Outperform
2017-11-03	Downgrade	First Analysis Sec	Overweight → Equal-Weight
2017-09-28	Downgrade	CL King	Buy → Neutral
2016-11-03	Reiterato	Cantor Fitzgerald	Buy
2016-06-27	Iniziato	CL King	Buy
2016-04-15	Iniziato	First Analysis Sec	Overweight
2016-02-04	Downgrade	Piper Jaffray	Overweight → Neutral
2016-01-04	Reiterato	Cantor Fitzgerald	Buy
2015-10-23	Aggiornamento	Piper Jaffray	Neutral → Overweight
2015-08-27	Iniziato	Cantor Fitzgerald	Buy
2015-02-04	Reiterato	Maxim Group	Buy
2013-09-26	Reiterato	Maxim Group	Buy
2013-01-14	Reiterato	Maxim Group	Buy

Mostra tutto

Pacific Biosciences Of California Inc Borsa (PACB) Ultime notizie

12:46 PM

Can Pacific Biosciences of California Inc. stock resist market sell offsWeekly Market Report & Safe Capital Growth Tips - newser.com

12:46 PM

Nov 02, 2025

Will Pacific Biosciences of California Inc. continue its uptrend2025 Fundamental Recap & Real-Time Market Sentiment Alerts - newser.com

Nov 02, 2025

Does Pacific Biosciences of California Inc. stock trade at a discount to peersMarket Sentiment Report & Daily Stock Trend Reports - newser.com

Nov 02, 2025

Will Pacific Biosciences of California Inc. stock split attract more investorsTrade Risk Assessment & Weekly High Momentum Picks - newser.com

Nov 02, 2025

What makes Pacific Biosciences of California Inc. stock attractive to growth fundsEarnings Overview Summary & Expert Approved Momentum Ideas - newser.com

Nov 02, 2025

Is Pacific Biosciences of California Inc. (P09) stock resilient in recession scenariosOptions Play & Weekly Chart Analysis and Guides - newser.com

Nov 02, 2025

Analyzing recovery setups for Pacific Biosciences of California Inc. investorsMarket Sentiment Review & Growth Focused Stock Pick Reports - newser.com

Nov 02, 2025

Will Pacific Biosciences of California Inc. stock sustain high P E ratios2025 Growth vs Value & Scalable Portfolio Growth Methods - newser.com

Nov 02, 2025

Is Pacific Biosciences of California Inc. stock ready for a breakoutEarnings Risk Report & Long-Term Investment Growth Plans - newser.com

Nov 02, 2025

Why Pacific Biosciences of California Inc. stock is favored by top institutionsJuly 2025 Selloffs & Safe Entry Point Identification - newser.com

Nov 02, 2025

Nov 01, 2025

What analysts say about Pacific Biosciences of California Inc P09 stockAutomated Trading Signals & Small Capital Wealth Plans - earlytimes.in

Nov 01, 2025

How to build a custom watchlist for Pacific Biosciences of California Inc.Insider Buying & Safe Capital Allocation Plans - newser.com

Nov 01, 2025

Pacific Biosciences of California (NASDAQ:PACB) Shares Gap UpHere's What Happened - MarketBeat

Nov 01, 2025

Pacific Biosciences of California (NASDAQ:PACB) Shareholders Are up 16% This Past Week, but Still in the Red Over the Last Five Years - 富途牛牛

Nov 01, 2025

Carret Asset Management LLC Buys New Holdings in Pacific Biosciences of California, Inc. $PACB - MarketBeat

Nov 01, 2025